Business Description
Patrys Ltd
ISIN : AU000000PAB9
Total Employee Number:
23Description
Patrys Ltd is a biopharmaceutical company engaged in the development of a proprietary intravenous (IV) formulation of quetiapine and an antibody platform known as deoxymabs. Its development programs target therapeutic applications in cancer, inflammatory diseases, and other medical conditions. The company's pipeline includes clinical-stage and early-stage research and development programs.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.74 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 31 | |||||
3-Year EPS without NRI Growth Rate | 26.9 | |||||
3-Year FCF Growth Rate | 42.3 | |||||
3-Year Book Growth Rate | -62.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 14.45 | |||||
9-Day RSI | 29.7 | |||||
14-Day RSI | 39.44 | |||||
3-1 Month Momentum % | 55.17 | |||||
6-1 Month Momentum % | 60.71 | |||||
12-1 Month Momentum % | 281.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.8 | |||||
Quick Ratio | 3.8 | |||||
Cash Ratio | 3.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -7.01 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -322.66 | |||||
ROA % | -190.33 | |||||
ROIC % | -561.34 | |||||
3-Year ROIIC % | -175.33 | |||||
ROC (Joel Greenblatt) % | -123228.57 | |||||
ROCE % | -308 | |||||
Moat Score | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 9.25 | |||||
EV-to-EBIT | -5.28 | |||||
EV-to-EBITDA | -5.28 | |||||
EV-to-FCF | -10.06 | |||||
Earnings Yield (Greenblatt) % | -18.94 | |||||
FCF Yield % | -9.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Patrys Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.02 | ||
| Beta | 1.8092 | ||
| 3-Year Sharpe Ratio | 0.08 | ||
| 3-Year Sortino Ratio | 0.18 | ||
| Volatility % | 182.15 | ||
| 14-Day RSI | 39.44 | ||
| 14-Day ATR (A$) | 0.002435 | ||
| 20-Day SMA (A$) | 0.04335 | ||
| 12-1 Month Momentum % | 281.84 | ||
| 52-Week Range (A$) | 0.011785 - 0.052 | ||
| Shares Outstanding (Mil) | 666.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Patrys Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Patrys Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.0666667:1 Stock Split | 2025-10-13 | 0.03 (+0.00%) | ||
| 1:1 Stock Split | 2009-07-01 | 1.36 (-3.70%) |
Show
Entries
Patrys Ltd Frequently Asked Questions
What is Patrys Ltd(ASX:PABDA)'s stock price today?
The current price of ASX:PABDA is A$0.04. The 52 week high of ASX:PABDA is A$0.05 and 52 week low is A$0.01.
When is next earnings date of Patrys Ltd(ASX:PABDA)?
The next earnings date of Patrys Ltd(ASX:PABDA) is .
Does Patrys Ltd(ASX:PABDA) pay dividends? If so, how much?
Patrys Ltd(ASX:PABDA) does not pay dividend.
Press Release
Articles on Patrys Ltd
No articles.